Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KIF18A inhibitor GH2616

An orally bioavailable inhibitor of the human kinesin-like protein KIF18A, with potential antineoplastic activity. Upon oral administration, KIF18A inhibitor GH2616 selectively binds to and inhibits the activity of KIF18A. This may result in multipolar cell division and inhibit tumor cell proliferation. KIF18A, a mitotic kinesin-8 motor protein, plays an important role in the regulation of chromosome positioning during cell division and is overexpressed in certain cancers. Certain cancer cells with chromosomal instability (CIN) features depend on KIF18A activity for bipolar spindle integrity and cell proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	GH 2616 GH-2616 GH2616

KIF18A inhibitor GH2616

Search NCI's Drug Dictionary